Latest Sunitinib Stories

2009-03-30 15:01:00

- Afinitor more than doubled time without tumor growth and reduced the risk of disease progression or death by 67% compared with placebo - Only once-daily oral cancer treatment to directly target mTOR, a protein inside the cell that controls tumor cell division and blood vessel growth - Phase III trials underway to explore potential of Afinitor in multiple additional cancers EAST HANOVER, N.J., March 30 /PRNewswire/ -- Novartis announced today that Afinitor(R) (everolimus) tablets has been...

2009-03-30 14:59:00

The U.S.

2009-03-16 10:00:00

NCCN presented new updates to the NCCN Clinical Practice Guidelines in Oncology(TM) for Thyroid Carcinoma at the NCCN 14th Annual Conference on March 14.

2009-03-13 07:15:00

Pfizer Inc. announced on Thursday that it had halted a successful trial of its cancer drug Sutent after results showed the drug slowed the progression of a rare form of pancreatic cancer.

2009-02-26 07:00:00

Pfizer's Axitinib Earns Decision Resources' Gold-Standard for Renal Cell Carcinoma in 2012, According to a New Report from Decision Resources WALTHAM, Mass., Feb.

2008-12-12 23:30:46

A British oncologist says he is dismayed that kidney cancer patients may be denied four new treatments due to cost. Dr.

2008-11-11 09:00:47

EntreMed, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, has met the primary endpoint for the efficacy portion of the open label Phase I/II study of MKC-1 in combination with pemetrexed in non-small cell lung cancer patients.

2008-10-27 12:00:30

Infinity Pharmaceuticals, a cancer drug discovery and development company, has initiated a Phase III registration trial of IPI-504, its lead inhibitor of heat shock protein 90, in patients with refractory gastrointestinal stromal tumors.

2008-10-23 09:00:38

ZymoGenetics, a developer of novel protein therapeutics, has announced positive interim results from a Phase II clinical trial evaluating interleukin 21 in combination with Nexavar tablets in patients with metastatic renal cell cancer.

2008-10-22 15:00:13

CAMBRIDGE, Mass., Oct. 22 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced new data from early non-clinical studies of Millennium/Takeda-discovered pipeline molecules highlighting novel therapeutic pathways in oncology.

Word of the Day
  • The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
  • A sleeping-potion; a soporific.
  • To mutter deliriously.
The word 'dwale' comes from an Old English word meaning 'error, doubt, delusion.'